INSM stock on watch after financing agreements to raise $500M (NASDAQ:INSM)
seekingalpha.com
finance
2022-10-19 12:46:51

Daniel Grizelj Insmed Incorporated (NASDAQ:INSM), a biotech focused on rare diseases, announced two financing deals with certain investment funds on Wednesday to raise $500M via a term loan and royalty sales. The loan agreement with a group of funds managed by Pharmakon Advisors, LP provides the company with a $350M term loan that matures on October 29, 2027, and is payable in eight equal quarterly payments. INSM has also entered into a financing agreement with OrbiMed Royalty & Credit Opportunities IV, LP to raise $150M less transaction expenses in return for royalties from global net sales of antibacterial therapy ARIKAYCE and experimental drug brensocatib.
